Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Sagimet Biosciences Inc Series A (SGMT)

Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes GlobeNewswire - Mon Jun 29, 6:00AM CDT

SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 7.74 (+1.71%)
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Jun 22, 7:49PM CDT

SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 7.74 (+1.71%)
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH GlobeNewswire - Wed May 27, 6:00AM CDT

Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid...

SGMT : 7.74 (+1.71%)
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ GlobeNewswire - Wed May 13, 6:00AM CDT

SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 7.74 (+1.71%)
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates GlobeNewswire - Tue May 12, 6:30AM CDT

Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of...

SGMT : 7.74 (+1.71%)
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago GlobeNewswire - Mon May 11, 6:00AM CDT

Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne  Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate...

SGMT : 7.74 (+1.71%)
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock GlobeNewswire - Mon Apr 27, 6:15AM CDT

SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 7.74 (+1.71%)
Sagimet Biosciences Provides Strategic and Corporate Updates GlobeNewswire - Mon Apr 27, 6:00AM CDT

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S.  planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567...

SGMT : 7.74 (+1.71%)
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer GlobeNewswire - Mon Apr 20, 6:00AM CDT

SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 7.74 (+1.71%)
OMER : 10.34 (+11.42%)
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Apr 6, 6:00AM CDT

SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 7.74 (+1.71%)

Barchart Exclusives

AVGO Stock Alert: What to Know as Broadcom, Apple Announce Expanded 5-Year Chip Deal Barchart - 12 minutes ago
Broadcom stock rallied today as Apple extends chip deal through 2031. Here’s why the announcement is bullish for AVGO shares. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.